Bactericidal/Permeability-Increasing Fold-Containing Family B Member 4 May Be Associated with NSAID-Induced Enteropathy.
Adult
Anti-Inflammatory Agents, Non-Steroidal
/ adverse effects
Capsule Endoscopy
Celecoxib
/ adverse effects
Female
Genome-Wide Association Study
Humans
Intercellular Signaling Peptides and Proteins
Intestinal Diseases
/ chemically induced
Intestinal Mucosa
/ pathology
Intestine, Small
/ pathology
Male
Middle Aged
Phenylpropionates
/ adverse effects
Phosphoproteins
/ genetics
Polymorphism, Single Nucleotide
BPI
Capsule endoscopy
Enteropathy
GWAS
NSAID
Small intestinal injury
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
05
07
2018
accepted:
19
10
2018
pubmed:
1
11
2018
medline:
26
3
2019
entrez:
1
11
2018
Statut:
ppublish
Résumé
There is considerable individual variability in nonsteroidal anti-inflammatory drug (NSAID)-induced enteropathy. To identify the SNP that is most significantly involved with NSAID-induced enteropathy. One hundred fifty human subjects who were known to have a certain degree of loxoprofen- or celecoxib-induced small-intestinal damage from a previous study were enrolled. The subjects were divided into groups based on treatments and also on the increased number of small intestinal mucosal breaks. The candidate SNP was selected by an initial analysis of GWAS among the groups in various combinations. After the initial analysis, the gene including the specified SNP was analyzed in detail using GWAS and genotype imputation. After analysis, 70 subjects receiving the loxoprofen treatment and 69 subjects receiving celecoxib treatment were determined to be eligible for the analysis. The minimum p value in GWAS was detected in the analysis of 16 cases with an increase of five or more mucosal breaks and 123 controls with zero to four mucosal breaks. In the GWAS, five SNPs in the bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4) gene showed the lowest p value (p = 2.69 × 10 The results indicate that SNPs in BPIFB4 were associated with NSAID-induced small intestinal mucosal injury (UMIN: 000007936).
Sections du résumé
BACKGROUND
There is considerable individual variability in nonsteroidal anti-inflammatory drug (NSAID)-induced enteropathy.
AIM
To identify the SNP that is most significantly involved with NSAID-induced enteropathy.
METHODS
One hundred fifty human subjects who were known to have a certain degree of loxoprofen- or celecoxib-induced small-intestinal damage from a previous study were enrolled. The subjects were divided into groups based on treatments and also on the increased number of small intestinal mucosal breaks. The candidate SNP was selected by an initial analysis of GWAS among the groups in various combinations. After the initial analysis, the gene including the specified SNP was analyzed in detail using GWAS and genotype imputation.
RESULTS
After analysis, 70 subjects receiving the loxoprofen treatment and 69 subjects receiving celecoxib treatment were determined to be eligible for the analysis. The minimum p value in GWAS was detected in the analysis of 16 cases with an increase of five or more mucosal breaks and 123 controls with zero to four mucosal breaks. In the GWAS, five SNPs in the bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4) gene showed the lowest p value (p = 2.69 × 10
CONCLUSION
The results indicate that SNPs in BPIFB4 were associated with NSAID-induced small intestinal mucosal injury (UMIN: 000007936).
Identifiants
pubmed: 30377885
doi: 10.1007/s10620-018-5349-0
pii: 10.1007/s10620-018-5349-0
pmc: PMC6514250
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
BPIFB4 protein, human
0
Intercellular Signaling Peptides and Proteins
0
Phenylpropionates
0
Phosphoproteins
0
loxoprofen
3583H0GZAP
Celecoxib
JCX84Q7J1L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
401-408Références
Antimicrob Agents Chemother. 2000 Nov;44(11):2925-31
pubmed: 11036002
Gut. 1992 Sep;33(9):1204-8
pubmed: 1427372
Eur J Pharmacol. 2004 Oct 1;500(1-3):427-39
pubmed: 15464050
Clin Gastroenterol Hepatol. 2005 Jan;3(1):55-9
pubmed: 15645405
Clin Gastroenterol Hepatol. 2005 Feb;3(2):133-41
pubmed: 15704047
Gastroenterology. 2005 May;128(5):1172-8
pubmed: 15887101
Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73
pubmed: 15952098
PLoS Genet. 2006 Dec;2(12):e190
pubmed: 17194218
Aliment Pharmacol Ther. 2007 May 15;25(10):1211-22
pubmed: 17451567
Clin Chim Acta. 2007 Sep;384(1-2):12-23
pubmed: 17678885
Gastroenterology. 2007 Aug;133(2):465-71
pubmed: 17681167
Trends Immunol. 2008 Nov;29(11):541-7
pubmed: 18838299
Gastrointest Endosc. 2009 Jun;69(7):1339-46
pubmed: 19243767
Digestion. 2010;82(3):167-72
pubmed: 20588029
Bioinformatics. 2010 Sep 15;26(18):2336-7
pubmed: 20634204
J Gastroenterol. 2011 Jan;46(1):57-64
pubmed: 20924615
Gastroenterology. 2011 Oct;141(4):1314-22, 1322.e1-5
pubmed: 21745447
Biochem Soc Trans. 2011 Aug;39(4):961-5
pubmed: 21787330
Circ Res. 2015 Jul 31;117(4):333-45
pubmed: 26034043
J Clin Gastroenterol. 2016 Mar;50(3):218-26
pubmed: 26166140
Nat Protoc. 2015 Sep;10(9):1285-96
pubmed: 26226460
Aging (Albany NY). 2017 Jan 22;9(2):370-380
pubmed: 28121621
Cardiovasc Res. 2017 Jun 1;113(7):795-804
pubmed: 28419216
Sci Rep. 2017 Aug 29;7(1):9706
pubmed: 28852218
Gastroenterology. 2018 Feb;154(3):500-514
pubmed: 29221664
Lancet. 1984 Nov 24;2(8413):1171-4
pubmed: 6150232